These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 2720678

  • 21. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
    Hong CI, Bernacki RJ, Hui SW, Rustum Y, West CR.
    Cancer Res; 1990 Jul 15; 50(14):4401-6. PubMed ID: 2364392
    [Abstract] [Full Text] [Related]

  • 22. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V, Kemena A, Keating MJ, Plunkett W.
    Cancer Res; 1992 Feb 15; 52(4):897-903. PubMed ID: 1737352
    [Abstract] [Full Text] [Related]

  • 23. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
    Taub JW, Huang X, Ge Y, Dutcher JA, Stout ML, Mohammad RM, Ravindranath Y, Matherly LH.
    Cancer Res; 2000 Nov 15; 60(22):6421-6. PubMed ID: 11103808
    [Abstract] [Full Text] [Related]

  • 24. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Hug V, Keating MJ, Chubb S.
    Cancer Res; 1980 Mar 15; 40(3):588-91. PubMed ID: 6937239
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
    Ueda T, Kamiya K, Urasaki Y, Wataya S, Kawai Y, Tsutani H, Sugiyama M, Nakamura T.
    Cancer Res; 1994 Jan 01; 54(1):109-13. PubMed ID: 8261429
    [Abstract] [Full Text] [Related]

  • 29. Effect of tetrahydrouridine on the action of 1-beta-D-arabinofuranosylcytosine in synchronized cultures of normal rat kidney cells.
    Wan CW, Mak TW.
    Cancer Res; 1979 Oct 01; 39(10):3981-5. PubMed ID: 476637
    [Abstract] [Full Text] [Related]

  • 30. Role of uridine triphosphate in the phosphorylation of 1-beta-D-arabinofuranosylcytosine by Ehrlich ascites tumor cells.
    White JC, Hines LH.
    Cancer Res; 1987 Apr 01; 47(7):1820-4. PubMed ID: 3028615
    [Abstract] [Full Text] [Related]

  • 31. Correlation of mouse tissue distribution of arabinosylcytosine in vivo with enzymatic activities in vitro.
    Ho DH.
    Drug Metab Dispos; 1976 Apr 01; 4(3):296-300. PubMed ID: 6236
    [Abstract] [Full Text] [Related]

  • 32. Cellular phosphorylation of 1-beta-D-arabinofuranosylcytosine 5-azacytidine with intact fibrosarcoma and leukemic cells.
    Lee T, Karon M, Monparler RL.
    Cancer Res; 1975 Sep 01; 35(9):2506-10. PubMed ID: 50132
    [Abstract] [Full Text] [Related]

  • 33. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
    Danhauser LL, Rustum YM.
    Cancer Res; 1985 May 01; 45(5):2002-7. PubMed ID: 3986756
    [Abstract] [Full Text] [Related]

  • 34. Pharmacology studies of 1-beta-D-arabinofuranosylcytosine in pediatric patients with leukemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug.
    Avramis VI, Weinberg KI, Sato JK, Lenarsky C, Willoughby ML, Coates TD, Ozkaynak MF, Parkman R.
    Cancer Res; 1989 Jan 01; 49(1):241-7. PubMed ID: 2908850
    [Abstract] [Full Text] [Related]

  • 35. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours.
    Kreis W, Chan K, Budman DR, Schulman P, Allen S, Weiselberg L, Lichtman S, Henderson V, Freeman J, Deere M.
    Cancer Res; 1988 Mar 01; 48(5):1337-42. PubMed ID: 3342412
    [Abstract] [Full Text] [Related]

  • 36. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia.
    Gandhi V, Xu YZ, Estey E.
    Clin Cancer Res; 1998 Jul 01; 4(7):1719-26. PubMed ID: 9676847
    [Abstract] [Full Text] [Related]

  • 37. Pharmacological study of modified intermediate-dose cytarabine therapy in patients with acute myeloid leukemia.
    Sutoh H, Yamauchi T, Gotoh N, Sugiyama M, Ueda T.
    Anticancer Res; 2003 Jul 01; 23(6D):5037-42. PubMed ID: 14981964
    [Abstract] [Full Text] [Related]

  • 38. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V, Estey E, Du M, Keating MJ, Plunkett W.
    Clin Cancer Res; 1997 Sep 01; 3(9):1539-45. PubMed ID: 9815841
    [Abstract] [Full Text] [Related]

  • 39. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K, Tsuruo T, Naganuma K, Tsukagoshi S, Sakurai Y.
    Cancer Res; 1984 Jan 01; 44(1):172-7. PubMed ID: 6690034
    [Abstract] [Full Text] [Related]

  • 40. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W, Nowak B, Keating MJ.
    Cancer Treat Rep; 1987 May 01; 71(5):479-83. PubMed ID: 3567973
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.